“SC”的搜索结果，显示 1-10 项，共有 1048 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

2. 综合卒中– 入院至皮肤穿刺的时间- 妙佑医疗国际

   SC: Mayo Clinic Breadcrumb. 关于妙佑医疗国际 · 质量和妙佑医疗国际 · 质量指标. Sections 质量指标. 亚利桑那州 · 佛罗里达州 · 明尼苏达州院区 · 事件报告 · 质量指标

3. 《无意外账单法案》 - 妙佑医疗国际

   SC: Mayo Clinic Breadcrumb. 主页 · 保险和账单. Sections 保险和账单. 抵达前. Collapse 抵达前. 患者检查表 · 服务前押金 · 登记 · 国际患者 · 常见问答 · 保险

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

7. 胃肠病科和肝病科- 临床试验- 妙佑医疗国际

   The purpose of this study is to assess the pharmacodynamics (PD) of HM15211 after administration of multiple subcutaneous (SC) doses compared to placebo on ...

8. 胃肠病科和肝病科- 临床试验- 妙佑医疗国际

   The purpose of this study is to assess the pharmacodynamics (PD) of HM15211 after administration of multiple subcutaneous (SC) doses compared to placebo on ...

9. Untitled

   Page 1.

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    The purpose of this study is to demonstrate pharmacokinetic non-inferiority for nivolumab + relatlimab FDC SC (fixed-dose combination for subcutaneous ...